Sandra Swain, M.D. has served as a member of the Board since April 2024. Dr. Swain has served as Associate Dean for Research Development at Georgetown University Medical Center since July 2016 and as Professor of Medicine at Georgetown University Medical Center since June 2007. She has also served as Vice President of Genetic Medicine at MedStar Health, a not-for-profit healthcare system, since January 2018. In her primary role as Associate Dean for Research Development, Dr. Swain works closely with industry and community partners to improve patients access to cutting-edge treatments and technologies by expanding medical research opportunities both at Georgetown University Medical Center and across the MedStar Health system. Dr. Swain previously served on the board of directors of Seagen, Inc. from November 2022 until its acquisition by Pfizer in December 2023. Dr. Swain holds a M.D. from the University of Florida and a B.A. in Chemistry from the University of North Carolina at Chapel Hill. Dr. Swain completed a residency in Internal Medicine at Vanderbilt University and a fellowship in Medical Oncology at the National Institutes of Health, National Cancer Institute. The Nominating Committee and the Board believe that Dr. Swain is qualified to serve on the Board due to her extensive research and clinical trial experience, particularly in oncology, and her public company and non-profit board experience.